Altimmune, Inc. (ALT)
$
3.83
-0.06 (-1.57%)
Key metrics
Financial statements
Free cash flow per share
-1.0013
Market cap
338 Million
Price to sales ratio
16.9 Thousand
Debt to equity
0.0982
Current ratio
20.4362
Income quality
0.9296
Average inventory
0
ROE
-0.6263
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for obesity and liver diseases. Its lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), acts as a GLP-1/glucagon dual receptor agonist and is currently undergoing a Phase 1b clinical trial targeting obesity and non-alcoholic steatohepatitis. Additionally, Altimmune is advancing HepTcell, an immunotherapeutic product candidate in Phase 2 trials for patients with chronic hepatitis B virus infections. The company incurred an interest expense of $9,000.00 reflecting its debt servicing obligations. The financial data pertains to the fiscal year 2024. Furthermore, the diluted EPS is -$1.34 accounting for potential share dilution, while the net income ratio stands at -4,752.95 showcasing the company's profitability margin. The operating income ratio is -5,158.60 indicating the company's operational profitability margin. Founded in 1997 and rebranded from Vaxin Inc. in September 2015, Altimmune is headquartered in Gaithersburg, Maryland. In the financial landscape, Altimmune's stock is currently affordable at $3.78 making it suitable for budget-conscious investors. The stock has a high average trading volume of 2,825,029.00 indicating robust liquidity that attracts traders. With a market capitalization of $338,025,279.00 the company is classified as a small-cap player, which often allows for significant growth potential. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, where it is driving innovation and growth, highlighting its role in shaping future therapies and treatments in its field.
Is Altimmune, Inc. (ALT) a good investment?
Investing in Altimmune, Inc. (ALT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Altimmune, Inc. (ALT)'s stock forecast?
Analysts predict Altimmune, Inc. stock to fluctuate between $2.90 (low) and $11.16 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Altimmune, Inc.'s market capitalization?
As of 2025-10-17, Altimmune, Inc.'s market cap is $338,025,279, based on 88,257,253 outstanding shares.
How does Altimmune, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Altimmune, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Altimmune, Inc. pay dividends?
Altimmune, Inc. pays dividends. The current dividend yield is 1,310.82%, with a payout of $291 per share.
How can I buy Altimmune, Inc. (ALT) stock?
To buy Altimmune, Inc. (ALT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALT. Place an order (Market, Limit, etc.).
What is the best time to invest in Altimmune, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Altimmune, Inc. stock ever split?
Altimmune, Inc.'s last stock split was 1:30 on 2018-09-14.
How did Altimmune, Inc. perform in the last earnings report?
Revenue: $20,000 | EPS: -$1.34 | Growth: -19.28%.
Where can I find Altimmune, Inc.'s investor relations reports?
Visit https://altimmune.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Altimmune, Inc.?
You can explore historical data from here
What is the all-time high and low for Altimmune, Inc. stock?
All-time high: $23.49 (2022-09-02) | All-time low: $2.09 (2023-10-23).
What are the key trends affecting Altimmune, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that 24-week data from its Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) will be presented in late-breaking oral and poster presentations at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C.
globenewswire.com
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
businesswire.com
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the "Company," "our" or "ALT5") (NASDAQ: ALTS) (FRA:5AR1), the $WLFI digital asset treasury company, today announced that it will participate in A.G.P. (Alliance Global Partners) Digital Assets & Technology (DAT) Showcase on October 8, 2025, at 9:00 a.m. ET. The presentation will feature Jonathan Hugh, Chief Financial Officer of ALT5 Sigma, alongside Zak Folkman, Co-Founder of World Liberty Financial, and Matt Morgan, Advisor to World Libe.
prnewswire.com
LOS ANGELES , Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 10, 2023 and June 25, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before October 6, 2025.
globenewswire.com
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
businesswire.com
NEW YORK--(BUSINESS WIRE)-- #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm h.
prnewswire.com
NEW YORK , Oct. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
globenewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
globenewswire.com
NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT) and certain of its officers.
globenewswire.com
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
See all news
